CN100590130C - 抗癌活性肽 - Google Patents
抗癌活性肽 Download PDFInfo
- Publication number
- CN100590130C CN100590130C CN200710035478A CN200710035478A CN100590130C CN 100590130 C CN100590130 C CN 100590130C CN 200710035478 A CN200710035478 A CN 200710035478A CN 200710035478 A CN200710035478 A CN 200710035478A CN 100590130 C CN100590130 C CN 100590130C
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- cancer
- present
- cells
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 74
- 230000001093 anti-cancer Effects 0.000 title abstract description 21
- 229920001184 polypeptide Polymers 0.000 claims abstract description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 51
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 37
- 241000067868 Lycosa singoriensis Species 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 11
- 230000006907 apoptotic process Effects 0.000 abstract description 8
- 201000011510 cancer Diseases 0.000 abstract description 8
- 231100000419 toxicity Toxicity 0.000 abstract description 8
- 230000001988 toxicity Effects 0.000 abstract description 8
- 230000012010 growth Effects 0.000 abstract description 5
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 4
- 201000010881 cervical cancer Diseases 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 231100000053 low toxicity Toxicity 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 3
- 201000007270 liver cancer Diseases 0.000 abstract description 3
- 208000014018 liver neoplasm Diseases 0.000 abstract description 3
- 201000005202 lung cancer Diseases 0.000 abstract description 3
- 208000020816 lung neoplasm Diseases 0.000 abstract description 3
- 239000002435 venom Substances 0.000 abstract description 3
- 231100000611 venom Toxicity 0.000 abstract description 3
- 210000001048 venom Anatomy 0.000 abstract description 3
- 206010021143 Hypoxia Diseases 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 230000002103 transcriptional effect Effects 0.000 abstract description 2
- 230000000975 bioactive effect Effects 0.000 abstract 3
- 230000018109 developmental process Effects 0.000 abstract 2
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 14
- 231100000614 poison Toxicity 0.000 description 8
- 239000002574 poison Substances 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000011275 oncology therapy Methods 0.000 description 5
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000000412 Annexin Human genes 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 101150080924 CNE1 gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710035478A CN100590130C (zh) | 2007-07-31 | 2007-07-31 | 抗癌活性肽 |
PCT/CN2008/071804 WO2009015602A1 (en) | 2007-07-31 | 2008-07-30 | Polypeptides having anticancer activity |
JP2010518485A JP5707594B2 (ja) | 2007-07-31 | 2008-07-30 | 抗癌活性ペプチド |
EP20080783797 EP2184295B1 (en) | 2007-07-31 | 2008-07-30 | Polypeptides having anticancer activity |
US12/697,320 US8207122B2 (en) | 2007-07-31 | 2010-02-01 | Anti-cancer bioactive peptides isolated from crude venom of Xinjiang Lycosa singoriensis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710035478A CN100590130C (zh) | 2007-07-31 | 2007-07-31 | 抗癌活性肽 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101168563A CN101168563A (zh) | 2008-04-30 |
CN100590130C true CN100590130C (zh) | 2010-02-17 |
Family
ID=39389354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710035478A Expired - Fee Related CN100590130C (zh) | 2007-07-31 | 2007-07-31 | 抗癌活性肽 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8207122B2 (zh) |
EP (1) | EP2184295B1 (zh) |
JP (1) | JP5707594B2 (zh) |
CN (1) | CN100590130C (zh) |
WO (1) | WO2009015602A1 (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100590130C (zh) * | 2007-07-31 | 2010-02-17 | 厦门北大之路生物工程有限公司 | 抗癌活性肽 |
CN104109193B (zh) * | 2014-06-30 | 2017-04-26 | 边伟 | 一种抗癌活性肽变体及其应用 |
CN106563126B (zh) * | 2016-10-31 | 2020-04-14 | 湖南师范大学 | 一种狼蛛抗癌活性肽修饰的纳米金颗粒肿瘤靶向性系统及应用 |
CN106589097A (zh) * | 2017-01-17 | 2017-04-26 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN106699865A (zh) * | 2017-01-17 | 2017-05-24 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN106749592A (zh) * | 2017-01-17 | 2017-05-31 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN106589093A (zh) * | 2017-01-17 | 2017-04-26 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN106831970A (zh) * | 2017-01-17 | 2017-06-13 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN106589096A (zh) * | 2017-01-17 | 2017-04-26 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN106589095A (zh) * | 2017-01-17 | 2017-04-26 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN106699864A (zh) * | 2017-01-17 | 2017-05-24 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN106632639A (zh) * | 2017-01-17 | 2017-05-10 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN106589094A (zh) * | 2017-01-17 | 2017-04-26 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN106699863A (zh) * | 2017-01-17 | 2017-05-24 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN106632638A (zh) * | 2017-01-17 | 2017-05-10 | 李露青 | 一种抗癌活性肽变体及其应用 |
CN107496904B (zh) * | 2017-09-21 | 2020-03-17 | 中南大学 | 多肽Lycosin-Ⅰ在制备抗炎和抗弓形虫药物中的应用 |
CN107737332B (zh) * | 2017-09-30 | 2021-08-20 | 湖南师范大学 | 一种蜘蛛细胞毒活性肽在抗肿瘤药物研发中的应用 |
CN108546285B (zh) * | 2018-03-07 | 2021-10-26 | 武汉轻工大学 | 一种抗癌生物活性肽CB1a及其应用 |
CN115894629B (zh) * | 2022-11-28 | 2023-12-05 | 耿威 | 定向诱导间充质干细胞制备的活性肽及其制备方法与在治疗肺癌药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2792518B2 (ja) * | 1994-01-19 | 1998-09-03 | ファイザー・インコーポレーテッド | ゲオリコサ・リオグランデからの孔形成ペプチド |
WO2003101475A1 (en) * | 2002-05-31 | 2003-12-11 | Transmolecular Inc. | Treatment of cell proliferative disorders with chlorotoxin |
CN100590130C (zh) * | 2007-07-31 | 2010-02-17 | 厦门北大之路生物工程有限公司 | 抗癌活性肽 |
-
2007
- 2007-07-31 CN CN200710035478A patent/CN100590130C/zh not_active Expired - Fee Related
-
2008
- 2008-07-30 WO PCT/CN2008/071804 patent/WO2009015602A1/zh active Application Filing
- 2008-07-30 EP EP20080783797 patent/EP2184295B1/en not_active Not-in-force
- 2008-07-30 JP JP2010518485A patent/JP5707594B2/ja not_active Expired - Fee Related
-
2010
- 2010-02-01 US US12/697,320 patent/US8207122B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
Review Pharmacologically active spider peptide toxins. G.Corzo、P.Escoubas.CMLS.Cell.Mol.Life Sci,Vol.60 . 2003 |
Review Pharmacologically active spider peptide toxins. G.Corzo、P.Escoubas.CMLS.Cell.Mol.Life Sci,Vol.60. 2003 * |
Also Published As
Publication number | Publication date |
---|---|
US8207122B2 (en) | 2012-06-26 |
JP5707594B2 (ja) | 2015-04-30 |
EP2184295B1 (en) | 2015-04-22 |
EP2184295A4 (en) | 2010-10-20 |
US20100145012A1 (en) | 2010-06-10 |
EP2184295A1 (en) | 2010-05-12 |
JP2010534689A (ja) | 2010-11-11 |
CN101168563A (zh) | 2008-04-30 |
WO2009015602A1 (en) | 2009-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100590130C (zh) | 抗癌活性肽 | |
JP2010534689A5 (zh) | ||
CN110655556B (zh) | 一种免疫调节肽的制备及方法 | |
CN110590907B (zh) | 一种免疫调节肽的制备及分离纯化方法 | |
CN100584860C (zh) | 一种改建的抗菌肽及其制备方法和应用 | |
CN106977593A (zh) | 多胜肽、编码该多胜肽的核酸分子、以及该多胜肽的应用 | |
CN102408477A (zh) | 鹿角脱盘蛋白多肽及其制备方法和应用 | |
CN101041693B (zh) | 一种降血糖多肽及其应用 | |
CN110317245B (zh) | Lag-3蛋白亲和环肽及其应用 | |
CN110713546B (zh) | 靶向survivin-XIAP复合物的抗肿瘤多肽Sur-X与用途 | |
CN113004372B (zh) | 一种免疫多肽及其应用 | |
CN103848914B (zh) | 一种具抗凝活性的菲牛蛭素多肽及其制备方法与用途 | |
CN102250217A (zh) | 华南雨蛙促皮肤损伤修复多肽及其基因和应用 | |
CN109157656B (zh) | 一种双靶标肿瘤疫苗及其制备方法和应用 | |
CN111393507A (zh) | 一种与多种肿瘤细胞特异性结合的新型多肽及其用途 | |
CN114195858B (zh) | 多肽及其改造体和在制备抗炎杀菌药物中的应用 | |
CN107446024A (zh) | 一种可拮抗ddx3蛋白rna结合活性的多肽dip‑13及其应用 | |
CN113336829A (zh) | 靶向anp32a抗白血病的小分子肽及其制备方法和应用 | |
CN108295244A (zh) | 用于治疗乳腺肿瘤的多肽 | |
CN108101960B (zh) | 一种具有ace抑制活性和抗肿瘤的多肽分子及其制备方法 | |
CN108299556B (zh) | 一种治疗血液肿瘤的多肽 | |
Kostanyan et al. | A biologically active fragment of the differentiation factor of the HL-60 line cells: Identification and properties | |
CN110724179A (zh) | 一种抗肿瘤多肽及其制备方法和用途 | |
CN113214375B (zh) | 一种抗肿瘤僵蚕溶茧酶抑制剂及其纯化方法和应用 | |
CN111732633B (zh) | 一种抗肿瘤多肽和在制备抗肿瘤药物方面的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: WEIMING BIOMEDICINE CO., LTD. Free format text: FORMER NAME: BEIDAZHILU BIOLOGICAL ENGINEERING CO., LTD., XIAMEN |
|
CP03 | Change of name, title or address |
Address after: Beijing University Biological Park Jinshang road 361009 of Fujian Province, Xiamen torch hi tech Zone No. 80 Patentee after: SINOBIOWAY BIOMEDICINE Co.,Ltd. Address before: Xiamen City, Fujian province 361009 Jinshang Road No. 80 North Park Patentee before: Xiamen Bioway Biotech Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100217 |
|
CF01 | Termination of patent right due to non-payment of annual fee |